Data as of Q4 2025 (Dec 31, 2025)

Saturn V Capital Management LP

โ€ขCIK: 1964437โ€ขFiling: Q4 2025

**Saturn V Capital Management LP** manages $545M across a concentrated portfolio of 20 positions. The fund exhibits significant conviction in specific names, with ABVX anchoring the top holding at $87.5M. Further notable allocations include AMLX ($54.3M), COGT ($43.2M), and MRX ($42.2M). This structure suggests a focused, high-conviction approach within its investment mandate.

Total AUM
$544.9M
QoQ Performance
+19.5%
Positions
20
Top 10 Concentration
76.5%
Latest Filing
Q4 2025

Top Holdings Allocation

ABVX
AMLX
COGT
JAZZ
PCVX
DYN
PHAR
CELC
ABVX16.1%
AMLX10.0%
COGT7.9%
JAZZ7.7%
PCVX6.8%
DYN6.4%
PHARVARIS5.8%
CELC5.8%

๐Ÿ“ˆ Biggest Buys

ALMS
ALUMIS INC
NEW
5.6% of portfolio
XFOR
X4 PHARMACEUTICALS INC
NEW
4.3% of portfolio
IVVD
INVIVYD INC
NEW
3.5% of portfolio
IMMX
IMMIX BIOPHARMA INC
NEW
2.9% of portfolio
MNPR
MONOPAR THERAPEUTICS INC
+109.6%
3.9% of portfolio

๐Ÿ“‰ Biggest Sells

COGT
COGENT BIOSCIENCES INC
-39.9%
7.9% of portfolio
ABVX
ABIVAX SA
-19.0%
16.1% of portfolio
DYN
DYNE THERAPEUTICS INC
-33.1%
6.4% of portfolio
CELC
CELCUITY INC
-33.1%
5.8% of portfolio
CNTA
CENTESSA PHARMACEUTICALS PLC
-61.5%
1.3% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

CGON
CG ONCOLOGY INC
SOLD
$23.4M
XENE
XENON PHARMACEUTICALS INC
SOLD
$20.2M
2GH
MERUS N V
SOLD
$17.3M
LENZ
LENZ THERAPEUTICS INC
SOLD
$17.1M
NAMS
NEWAMSTERDAM PHARMA COMPANY
SOLD
$4.4M

Changes from Q3 2025

NEW8 new positions
โ†‘4 increased
โ†“8 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023